Diabetes Care, Vol 20, Issue 5 819-823, Copyright © 1997 by American Diabetes Association

ARTICLES

Glycosaminoglycans delay the progression of nephropathy in NIDDM

A Solini, L Vergnani, F Ricci and G Crepaldi
Department of Internal Medicine, University of Padova, Italy. flr@ifeuniv.unife.it

OBJECTIVE: To determine the effect of oral administration of glycosaminoglycans on metabolic control and albumin excretion rate (AER) in NIDDM patients with increased urinary albumin excretion. RESEARCH DESIGN AND METHODS: Twelve NIDDM hypertensive patients (age 52 +/- 3 years, HbA1c 7.7 +/- 0.2%) on antihypertensive treatment were enrolled in a double-blind placebo-controlled study, assuming either placebo or sulodexide (100 mg/day) for 4 months; at the end of this period, a crossover was performed. We have evaluated routine biochemical parameters plus AER and coagulative function every 2 months. RESULTS: Both plasma fibrinogen (from 4.15 +/- 0.32 to 2.77 +/- 0.47 mmol/l) and AER (from 128.3 +/- 40.6 to 39.6 +/- 11.9 micrograms/min) decreased significantly after treatment with glycosaminoglycans in respect to placebo; moreover, blood pressure control ameliorated, also in the absence of any variation of therapy. CONCLUSIONS: Glycosaminoglycan therapy, likely in association with a satisfactory control of blood pressure values, seems to prevent the progression of diabetic nephropathy in NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. L. Heerspink, T. Greene, J. B. Lewis, I. Raz, R. D. Rohde, L. G. Hunsicker, S. L. Schwartz, S. Aronoff, M. A. Katz, G. M. Eisner, et al. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1946 - 1954. [Abstract] [Full Text] [PDF]

				J. L. Cirujeda and P. C. Granado A Study on the Safety, Efficacy, and Efficiency of Sulodexide Compared with Acenocoumarol in Secondary Prophylaxis in Patients with Deep Venous Thrombosis Angiology, January 1, 2006; 57(1): 53 - 64. [Abstract] [PDF]

				J. F.M. Lensen, A. L.W.M.M. Rops, T. J.M. Wijnhoven, T. Hafmans, W. F.J. Feitz, E. Oosterwijk, B. Banas, R. J.M. Bindels, L. P.W.J. van den Heuvel, J. van der Vlag, et al. Localization and Functional Characterization of Glycosaminoglycan Domains in the Normal Human Kidney as Revealed by Phage Display-Derived Single Chain Antibodies J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1279 - 1288. [Abstract] [Full Text] [PDF]

				B. M. Errichi, M. R. Cesarone, G. Belcaro, R. Marinucci, A. Ricci, A. Ippolito, R. Brandolini, G. Vinciguerra, M. Dugall, A. Felicita, et al. Prevention of Recurrent Deep Venous Thrombosis with Sulodexide: The SanVal Registry Angiology, May 1, 2004; 55(3): 243 - 249. [Abstract] [PDF]

				J. W. VAN DER PIJL, H. H. P. J. LEMKES, M. FRÖLICH, F. J. VAN DER WOUDE, F. J. M. VAN DER MEER, and L. A. VAN ES Effect of Danaparoid Sodium on Proteinuria, von Willebrand Factor, and Hard Exudates in Patients with Diabetes Mellitus Type 2 J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1331 - 1336. [Abstract] [Full Text]